“Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers,” said Trump-appointed FDA Commissioner Marty Makary.

The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations and pinpoint high-priority inspection targets.

Please select this link to read the complete article from Fast Company.